Ritchie, Scott C. http://orcid.org/0000-0002-8454-9548
Lambert, Samuel A. http://orcid.org/0000-0001-8222-008X
Arnold, Matthew http://orcid.org/0000-0001-6339-1115
Teo, Shu Mei
Lim, Sol http://orcid.org/0000-0001-7786-3355
Scepanovic, Petar
Marten, Jonathan
Zahid, Sohail
Chaffin, Mark http://orcid.org/0000-0002-1234-5562
Liu, Yingying
Abraham, Gad
Ouwehand, Willem H. http://orcid.org/0000-0002-7744-1790
Roberts, David J.
Watkins, Nicholas A.
Drew, Brian G. http://orcid.org/0000-0002-7839-9467
Calkin, Anna C. http://orcid.org/0000-0002-9861-0602
Di Angelantonio, Emanuele
Soranzo, Nicole http://orcid.org/0000-0003-1095-3852
Burgess, Stephen http://orcid.org/0000-0001-5365-8760
Chapman, Michael http://orcid.org/0000-0002-4582-6303
Kathiresan, Sekar http://orcid.org/0000-0002-3711-7101
Khera, Amit V.
Danesh, John
Butterworth, Adam S. http://orcid.org/0000-0002-6915-9015
Inouye, Michael http://orcid.org/0000-0001-9413-6520
Article History
Received: 14 May 2021
Accepted: 14 September 2021
First Online: 8 November 2021
Competing interests
: Several authors are now employed by or run pharmaceutical companies. All significant contributions to this study were made before these roles and the named companies had no role in the study. M.A. is an employee of AstraZeneca. P.S. is an employee of Roche. J.M. is an employee of Genomics PLC. G.A. is an employee of CSL Limited. S.K. is the chief executive officer of Verve Therapeutics. The other authors declare no competing interests.
Free to read: This content has been made available to all.